Mr. Stephen Van Deventer reports

PREVECEUTICAL ANNOUNCES FIRST TRANCHE CLOSING OF PRIVATE PLACEMENT

Further to the news release dated May 16, 2024, Preveceutical Medical Inc. has closed the first tranche of its non-brokered private placement for gross proceeds of $115,000 through the sale of 4.6 million units of the company at a price of 2.5 cents per unit.

Each unit consists of one common share in capital of the company and one-half of one common share purchase warrant. Each warrant entitles the holder thereof to purchase one common share at an exercise price of five cents for a period of 24 months from the date of issuance, provided that, if the closing price of the common shares on any Canadian stock exchange on which the common shares are then listed is at a price equal to or greater than eight cents for a period of 10 consecutive trading days, the company will have the right to accelerate the expiry date of the warrants by issuing a press release or other form of notice permitted by the certificates representing the warrants, announcing that the warrants will expire at 4 p.m. Vancouver time on a date that is not fewer than 30 days from the date notice is given.

The company paid the following finders' fees to certain finders in connection with the private placement: (i) an aggregate cash fee of $9,200; and (ii) an aggregate of 368,000 common share purchase warrants of the company, with each finder's warrant exercisable to acquire one common share at a price of five cents for a period of 24 months from the date of issuance.

The company intends to use the net proceeds of the offering for working capital purposes, including payment of audit-related fees.

In accordance with applicable securities laws, the securities offered pursuant to the private placement are subject to a statutory hold period of four months and a day from the date of issuance.

About Preveceutical Medical Inc.

Preveceutical is a health science company focused on developing innovative options for preventive and curative therapies, utilizing organic and nature identical products. The company aims to be a leader in the preventive health science sector.

With the completion of three of its research programs, the company is actively working on the development, clinical trials and commercialization of its products, and has filed a number of provisional patent applications to protect the intellectual property from its research programs.

We seek Safe Harbor.